Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

Conclusion: In non-GCB DLBCL cells, NF- κB downregulates PRDM1 and thereby promotesMDR1 transcription by terminating PRDM1-induced transcriptional inhibition ofMDR1. Such a mechanism may explain the reason for disease recurrence in non-GCB DLBCL after R-CHOP or combined CHOP with bortezomib treatment. Our findings may provide a potential therapeutic strategy for reducing drug resistance in patients with DLBCL.Chemotherapy
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research